5DRT
Crystal structure of Dot1L in complex with inhibitor CPD2 [2-(2-(5-((2-chlorophenoxy)methyl)-1H-tetrazol-1-yl)acetyl)-N-(4-chlorophenyl)hydrazinecarboxamide]
Functional Information from GO Data
Functional Information from PDB Data
| site_id | AC1 |
| Number of Residues | 15 |
| Details | binding site for residue 5EG A 401 |
| Chain | Residue |
| A | PHE131 |
| A | VAL169 |
| A | VAL240 |
| A | ASN241 |
| A | VAL267 |
| A | SER268 |
| A | SER269 |
| A | PRO133 |
| A | SER140 |
| A | ASP161 |
| A | GLY163 |
| A | SER164 |
| A | GLY165 |
| A | VAL166 |
| A | GLN168 |
| site_id | AC2 |
| Number of Residues | 4 |
| Details | binding site for residue K B 1001 |
| Chain | Residue |
| B | LYS52 |
| B | LEU53 |
| B | MET55 |
| B | ASN57 |
| site_id | AC3 |
| Number of Residues | 17 |
| Details | binding site for residue 5EG B 1002 |
| Chain | Residue |
| B | PHE131 |
| B | PRO133 |
| B | TYR136 |
| B | SER140 |
| B | ASP161 |
| B | GLY163 |
| B | SER164 |
| B | GLY165 |
| B | VAL166 |
| B | GLN168 |
| B | VAL169 |
| B | PHE239 |
| B | VAL240 |
| B | ASN241 |
| B | VAL267 |
| B | SER268 |
| B | SER269 |
Functional Information from SwissProt/UniProt
| site_id | SWS_FT_FI1 |
| Number of Residues | 10 |
| Details | Binding site: {"evidences":[{"source":"PubMed","id":"12628190","evidenceCode":"ECO:0000269"},{"source":"PDB","id":"1NW3","evidenceCode":"ECO:0007744"}]} |
| Chain | Residue | Details |
| site_id | SWS_FT_FI2 |
| Number of Residues | 2 |
| Details | Binding site: {"evidences":[{"source":"PROSITE-ProRule","id":"PRU00902","evidenceCode":"ECO:0000255"},{"source":"PubMed","id":"12628190","evidenceCode":"ECO:0000269"},{"source":"PDB","id":"1NW3","evidenceCode":"ECO:0007744"}]} |
| Chain | Residue | Details |
| site_id | SWS_FT_FI3 |
| Number of Residues | 2 |
| Details | Modified residue: {"description":"Phosphoserine","evidences":[{"source":"PubMed","id":"23186163","evidenceCode":"ECO:0007744"}]} |
| Chain | Residue | Details |
